NewAmsterdam Pharma 's latest drug treatment could lead investors to a windfall, according to RBC Capital Markets. Timashev believes obicetrapib, a cholesterol-lowering treatment, "can succeed where others have failed" due to the drug's specific and idiosyncratic properties. Additionally, the drug has a history of success, consistently demonstrating a 40% to 50% LDL reduction in patients. The analyst added that while current use cases for the drug involve lowering cardiovascular events, there's also potential upside for other applications. Specifically, there's a relationship between higher cholesterol levels and Alzheimer's disease, which could be an avenue for NewAmsterdam to explore for future treatment opportunities.

---

Persons: Leonid Timashev, Timashev, obicetrapib, there's, — CNBC's Michael Bloom Organizations: NewAmsterdam Pharma, RBC Capital Markets